Comparative Pharmacology
Head-to-head clinical analysis: EOHILIA versus HYDELTRASOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EOHILIA versus HYDELTRASOL.
EOHILIA vs HYDELTRASOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EOHILIA (budesonide) is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and arachidonic acid metabolites, thereby reducing inflammation in the esophagus.
Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses multiple inflammatory cytokines and induces lipocortin synthesis.
For adults: 0.5 mg/kg IV every 2 weeks, infused over 60 minutes. Maximum single dose: 40 mg.
Intravenous: Initial dose 100-250 mg, then repeat every 10-30 minutes as needed. Intramuscular: 100-250 mg every 10-30 minutes. Intra-articular: 10-40 mg per joint every 1-2 weeks.
None Documented
None Documented
Terminal elimination half-life is 52 hours (steady state reached after 10-12 days of daily dosing)
Terminal half-life ~2-3 hours; clinically, adrenal suppression may persist >24h.
Renal (70% unchanged drug), fecal (12%) and biliary (5%)
Renally eliminated: ~80% as metabolites, <10% unchanged. Biliary/fecal: minor.
Category C
Category C
Corticosteroid
Corticosteroid